Promises
3 promises
Promise Tracker
0 delivered, 0 close, 3 missed.
View Promises →
Sunpharma Ltd — Q3 FY26
Sun Pharma delivered a strong Q3 FY26 with consolidated revenue of INR 15,469 crore (+15.1% YoY) and EBITDA of INR 4,949 crore (+23.4% YoY), driven by broad-based growth in India (+16.2%) and emerging markets (+21.6%), partially offset by flat US sales.
bullish
high
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Sun Pharma delivered a strong Q3 FY26 with consolidated revenue of INR 15,469 crore (+15.1% YoY) and EBITDA of INR 4,949 crore (+23.4% YoY), driven by broad-based growth in India (+16.2%) and emerging markets (+21.6%), partially offset by flat US sales. EBITDA margin expanded to 31.9% on better product mix, while PAT grew 16% to INR 3,369 crore despite a higher tax rate. Management highlighted the upcoming launch of generic semaglutide in India as a key growth catalyst, with approvals received for both diabetes and weight management. However, US generic sales remain under pressure from competition and manufacturing compliance issues, and the company faces uncertainty from proposed US pricing reforms. The strong balance sheet (net cash $3.2B) provides M&A flexibility, though management remains disciplined.
सन फार्मा की तीसरी तिमाही (अक्टूबर-दिसंबर 2025) में कमाई 15,469 करोड़ रुपये रही, जो पिछले साल से 15% ज्यादा है। भारत और उभरते बाजारों में बिक्री बढ़ने से मुनाफा भी 23% बढ़कर 4,949 करोड़ रुपये हो गया। अमेरिका में बिक्री सपाट रही। कंपनी का शुद्ध लाभ 16% बढ़कर 3,369 करोड़ रुपये हुआ। जल्द ही भारत में डायबिटीज और मोटापे की दवा 'जेनेरिक सेमाग्लूटाइड' लॉन्च होगी, जिससे कमाई बढ़ने की उम्मीद है। हालांकि, अमेरिका में सस्ती दवाओं की बिक्री पर प्रतिस्पर्धा और कारखानों की जांच का दबाव है। कंपनी के पास 3.2 अरब डॉलर नकद है, जिससे वह नई कंपनियां खरीद सकती है, लेकिन फिलहाल सावधानी बरत रही है।
Promises0 met · 3 missedRisks4 trackedTranscriptfull text
Research workspace
Focused Modules
Risks
4 risks
Risk Intelligence
US generic sales pressure from competition
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
India Formulation Sales
INR 4,999 crore
+16.2% YoY
India formulation sales grew 16.2% YoY to INR 49,986 million, driven by volume growth of 6.3% vs IPM volume growth of 1.2%.
Global Innovative Medicine Sales
$423 million
+14.3% YoY
Global innovative medicine sales grew 14.3% YoY to $423 million, including $55 million milestone income; ex-milestone growth was 13.2%.
US Formulation Sales
$477 million
+0.6% YoY
US sales were marginally up 0.6% to $477 million, with growth in innovative medicines offset by lower generic sales due to competition.
India Market Share
8.4%
+30 bps YoY
Sun Pharma's market share in the Indian pharmaceutical market improved to 8.4% from 8.1% a year ago, maintaining the #1 position.
What Changed vs Last Quarter
NEW
Semaglutide launch in India on patent expiry
Sun Pharma plans to launch generic semaglutide in India on day one of patent expiry for both chronic weight management and type 2 diabetes, under brands NovelTreat and SemaTrinity.
NEW
R&D spend guidance for next year
Management indicated they will provide R&D spend guidance for the next fiscal year in the next quarter's call.
NEW
Phase 2b trial for GL0034 to complete in 12-18 months
The phase 2b study for GL0034 in type 2 diabetes has started and is expected to complete within 12-18 months.
DROPPED
R&D spend at lower end of 6-8% of sales
Management expects full-year R&D spend to be at the lower end of the guided 6-8% range.
DROPPED
Unloxcyt launch in H2 FY26
Unloxcyt remains on track for US launch in the second half of FY26, with sales force already in place.
DROPPED
Ilumya psoriatic arthritis filing in H2 FY26
Sun Pharma plans to file Ilumya for psoriatic arthritis indication in the second half of FY26.
DROPPED
Incremental specialty spend of ~$100M in FY26
The company expects to spend around $100M in FY26 to support Leqselvi and Unloxcyt launches, with increases in Q3 and Q4.
NEW RISK
US generic sales pressure from competition
US generic sales declined due to additional competition on certain products, and recovery depends on resolving manufacturing compliance issues at several sites.
NEW RISK
Proposed US Most Favored Nation pricing models
CMS proposed pricing models could impact US revenues; management declined to share mitigation strategies, citing commercial sensitivity.
NEW RISK
Milestone income may not recur
Management noted that milestone income of $55 million in Q3 may not recur in future quarters, potentially impacting revenue comparability.
RISK GONE
US tariff uncertainty on innovative medicines
Potential tariffs on patented drug imports into the US could impact Sun Pharma's innovative portfolio, though generics are expected to be excluded.
RISK GONE
Lenalidomide revenue decline
Lenalidomide sales have dropped YoY and are expected to be minimal in the second half, impacting US generics revenue.
RISK GONE
Competition in alopecia areata market
Stagnation in prescriptions for existing targeted treatments could hinder Leqselvi's uptake, though management expects market growth.
🤫 Topics management stopped discussing
Mentioned in Q1 FY25, Q2 FY25, Q3 FY25, Q4 FY25
FY2026 R&D spend expected to be 6%-8% of sales.
Mentioned in Q1 FY25, Q2 FY26, Q4 FY25
ETR increased to 24.7% from 15.8% YoY due to expiry of tax benefits, expected to hover around 25%, pressuring net profit growth.
Mentioned in Q1 FY26, Q2 FY25
Sun Pharma plans to file for psoriatic arthritis indication for ILUMYA before end of calendar year 2025.
Mentioned in Q1 FY26, Q2 FY26
Unloxcyt remains on track for US launch in the second half of FY26, with sales force already in place.
Mentioned in Q1 FY25, Q4 FY25
Leqselvi to be launched in the US in the second quarter of FY2026.
Fast read
Guidance and risk preview
Sun Pharma plans to launch generic semaglutide in India on day one of patent expiry for both chronic weight management and type 2 diabetes, under b...
US generic sales declined due to additional competition on certain products, and recovery depends on resolving manufacturing compliance issues at s...
View Risks →